Ubiquity: A framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 41, Issue 2, 2014, Pages 141-151

  Harrold, John M ^a,b   Abraham, Anson K ^a  

^a PFIZER INC   (United States)

^b AMGEN INC   (United States)

Author keywords

ADAPT; Berkeley Madonna; Graphical user interface; MATLAB; PBPK

Indexed keywords

ANALYTICAL ERROR; ARTICLE; COMPUTER INTERFACE; COMPUTER MODEL; COMPUTER PROGRAM; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; WORKFLOW;

MODELS, BIOLOGICAL; PHARMACOKINETICS; SOFTWARE; USER-COMPUTER INTERFACE;

EID: 84897583591     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-014-9352-6     Document Type: Article

References (24)

1. Lipscomb JC, Haddad S, Poet T, Krishnan K (2012) Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment. In: Johanson G (ed) In technologies for toxicity. Springer, New York, pp 76-95
2. Abuqayyas L, Balthasar JP (2012) Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. Int J Pharm 439:8-16. doi: 10.1016/j.ijpharm.2012.09.042
3. Jones HM, Dickins M, Youdim K, Gosset JR, Attkins NJ, Hay TL et al (2012) Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica 42:94-106. doi: 10.3109/00498254.2011.627477
4. Iyengar R, Zhao S, Chung S-W, Mager DE, Gallo JM (2012) Merging systems biology with pharmacodynamics. Sci Transl Med 4:126-227. doi: 10.1126/scitranslmed.3003563
5. Luu KT, Kraynov E, Kuang B, Vicini P, Zhong W-Z (2013) Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies. AAPS J 15:551-558. doi: 10.1208/s12248-013-9464-8
6. Chien JY, Friedrich S, Heathman MA, Alwis DP, Sinha V (2005) Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 7:544-559. doi: 10.1208/aapsj070355
7. Lavé T, Parrott N, Grimm HP, Fleury A, Reddy M (2007) Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 37:1295-1310. doi: 10.1080/00498250701534885
8. Rosenthal RE (2006) GAMS - a user's guide. GAMS Development Corporation, Washington, DC
9. Harrold JM, Parker RS (2009) Clinically relevant cancer chemotherapy dose scheduling via mixed-integer optimization. Comput Chem Eng 33:2042-2054. doi: 10.1016/j
10. Fritzson P (2011) Introduction to modeling and simulation of technical and physical systems with modelica. Wiley, Hoboken
11. Hucka, M (2010) The systems biology markup language (SBML): language specification for level 3 version 1 core. http://sbml.org/Documents/ Specifications. Accessed 24 November 3013
12. Moodie, S L, Swat, M J, Kristensen, N R, Le Novère, N (2013). PharmML: the pharmacometrics markup language. Drug disease model resource. http://www.ddmore.eu/pharmml. Accessed 24 November 2013
13. Holford, N (2013). Model Coding Language Specification Draft 5 version 0.8. Drug Disease Model Resource. http://www.ddmore.eu/mdl. Accessed 24 November 2013
14. D'Argenio DZ, Schumitzky A, Wang X (2009) ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical simulations resource. University of Southern California, Los Angeles
15. Macey R, Oster G, Zahnley T (2000) Berkeley Madonna user's guide, Department of Molecular and Cellular Biology. University of California, Berkeley
16. Maiwald T, Timmer J (2008) Dynamical modeling and multi-experiment fitting with PottersWheel. Bioinformatics 24:2037-2043. doi: 10.1093/bioinformatics/btn350
17. Lavielle M, Mentré F (2007) Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn 34:229-249. doi: 10.1007/s10928-006-9043-z
18. Chan PLS, Jacqmin P, Lavielle M, McFadyen L, Weatherley B (2010) The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. J Pharmacokinet Biopharm 38:41-61. doi: 10.1007/s10928-010-9175-z
19. Mager DE (2006) Target-mediated drug disposition and dynamics. Biochem Pharmacol 72:1-10. doi: 10.1016/j.bcp.2005.12.041
20. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478. doi: 10.1007/BF01061691
21. Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:633-659. doi: 10.2165/11535960- 000000000-00000
22. Vieira P, Rajewsky K (1988) The half-lives of serum immunoglobulins in adult mice. Eur J Immunol 18:313-316. doi: 10.1002/eji.1830180221
23. Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Biopharm 39:67-86. doi: 10.1007/s10928-011- 9232-2
24. Beal SL, Sheiner LB, Boeckmann A, Bauer RJ (2009) NONMEM user's guides. (1989-2009). Icon Development Solutions, Ellicott City